Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Refining Targeted Therapy Opportunities for BRAF-Mutant Melanoma.

Cancer discovery - 1 Aug 2017

Jenkins Russell W, Barbie David A

Abstract excerpt

<b/> Identifying molecular and cellular features associated with resistance to targeted BRAF/MAPK pathway inhibition may guide development of novel therapeutic approaches. Integrated, comparative analysis of genomic and functional data in sensitive and resistant cell lines unveils novel targetable regulators of resistance to MAPK pathway inhibition in melanoma. Cancer Discov; 7(8); 799-801. ©2017 AACR.See related...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to BRAF gene
Share to MAP Kinase Kinase 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Molecular Targeted Therapy

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 28765115
DOI: 10.1158/2159-8290.CD-17-0607

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Refining Targeted Therapy Opportunities for BRAF-Mutant Melanoma.PMID 28765115Read ↗

Targeted therapy resistance mechanisms and therapeutic implications in melanoma.Semantic proximity Read ↗

Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).Semantic proximity Read ↗

Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma.Semantic proximity Read ↗

Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanomaSemantic proximity Read ↗

Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice.Semantic proximity Read ↗

Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials.Semantic proximity Read ↗

Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures.Semantic proximity Read ↗

New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances.Semantic proximity Read ↗

BRAF targeted therapy changes the treatment paradigm in melanoma.Semantic proximity Read ↗

Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.Semantic proximity Read ↗

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Semantic proximity Read ↗

Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.